For the quarter ending 2025-09-30, IKT has $79,594,541 in assets. $6,696,243 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 38,269,706 | 77,742,669 | ||
| Marketable securities | 39,052,511 | 9,923,100 | ||
| Prepaid research and development | 210,566 | 138,855 | ||
| Deferred offering costs | 385,062 | 307,373 | ||
| Prepaid expenses and other current assets | 618,783 | 682,628 | ||
| Total current assets | 78,536,628 | 88,794,625 | ||
| Equipment and improvements, net | 0 | 23,687 | ||
| Right-of-use asset | 0 | 34,918 | ||
| Prepaid research and development, noncurrent | 1,000,000 | - | ||
| Other assets | 57,913 | - | ||
| Total assets | 79,594,541 | 88,853,230 | ||
| Accounts payable | 620,528 | 2,703,554 | ||
| Lease obligation, current | 0 | 37,944 | ||
| Accrued expenses and other current liabilities | 3,656,383 | 3,145,888 | ||
| Contingent consideration liability | 2,419,332 | 2,912,159 | ||
| Total current liabilities | 6,696,243 | 8,799,545 | ||
| Total liabilities | 6,696,243 | 8,799,545 | ||
| Common stock, 0.001 par value 500,000,000 and 100,000,000 shares authorized 74,807,911 and 69,362,439 shares issued and outstanding (including 4,149,252 and 0 contingently issuable shares - see note 10) at september 30, 2025 and december 31, 2024, respectively | 74,808 | 74,516 | ||
| Additional paid-in capital | 202,772,828 | 197,996,982 | ||
| Accumulated other comprehensive loss | -4,189 | -2,944 | ||
| Accumulated deficit | -129,945,149 | -118,014,869 | ||
| Total stockholders' equity | 72,898,298 | 80,053,685 | ||
| Total liabilities and stockholders' equity | 79,594,541 | 88,853,230 | ||
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)